Axsome Therapeutics, Inc. $AXSM is Occam Crest Management LP’s 9th Largest Position

Occam Crest Management LP boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,000 shares of the company’s stock after acquiring an additional 2,000 shares during the quarter. Axsome Therapeutics comprises about 4.4% of Occam Crest Management LP’s holdings, making the stock its 9th largest holding. Occam Crest Management LP owned approximately 0.07% of Axsome Therapeutics worth $6,392,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. TritonPoint Partners LLC purchased a new position in shares of Axsome Therapeutics during the 4th quarter valued at approximately $209,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Axsome Therapeutics by 4.2% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 2,190 shares of the company’s stock valued at $400,000 after buying an additional 89 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Axsome Therapeutics by 71.4% during the 4th quarter. Verition Fund Management LLC now owns 3,409 shares of the company’s stock valued at $623,000 after buying an additional 1,420 shares during the last quarter. MML Investors Services LLC bought a new position in Axsome Therapeutics during the fourth quarter worth $436,000. Finally, Nicholas Investment Partners LP lifted its stake in Axsome Therapeutics by 88.2% during the fourth quarter. Nicholas Investment Partners LP now owns 91,564 shares of the company’s stock worth $16,723,000 after purchasing an additional 42,907 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 33,000 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the sale, the chief financial officer directly owned 42,867 shares of the company’s stock, valued at $10,291,938.03. This trade represents a 43.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 49,670 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $241.01, for a total value of $11,970,966.70. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,742,261.29. This trade represents a 87.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 113,686 shares of company stock worth $26,666,006. 20.60% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Trading Down 0.7%

Shares of NASDAQ AXSM opened at $253.40 on Tuesday. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $257.92. The firm has a market capitalization of $13.04 billion, a PE ratio of -67.94 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. The business has a 50-day moving average price of $212.64 and a two-hundred day moving average price of $182.89.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. The business’s revenue was up 57.4% on a year-over-year basis. As a group, analysts predict that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on AXSM shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $272.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Wolfe Research began coverage on Axsome Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $230.00 target price on the stock. Needham & Company LLC lifted their target price on Axsome Therapeutics from $225.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Wells Fargo & Company increased their price target on Axsome Therapeutics from $225.00 to $255.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Finally, Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $256.79.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.